Theragnostics Ltd has appointed Dennis Langer and Ken Herrmann as non-executive directors to help guide development of its radionuclide diagnostics and therapies. Dr Langer formerly held executive positions at Neose Technologies Inc and GlaxoSmithKline Plc. He currently is a director of the Whitehead Institute for Biomedical Research in Cambridge, Mass, US. Professor Herrmann is chair of the department of nuclear medicine at Universitätsklinikum Essen in Germany and is an expert in the clinical development of radiopharmaceuticals.
Theragnostics announced the appointments on 4 August 2021.
Copyright 2021 Evernow Publishing Ltd